Journal Article

A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D<sub>3</sub> regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats

Michinori Hirata, Koichi Endo, Hiroyuki Ohkawa, Kenji Kumaki, Noboru Kubodera, Eduardo Slatopolsky, Kiyoshi Kurokawa and Masafumi Fukagawa

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_10, pages 37-40
Published in print October 2002 | ISSN: 0931-0509
Published online October 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.suppl_10.37
A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D3 regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats

Show Summary Details

Preview

Background. 1,25-Dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT) is an analogue of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol) with less calcaemic activity, thus more suitable than 1,25(OH)2D3 for the control of parathyroid hormone (PTH) secretion in chronic dialysis patients. As the low-calcaemic action of OCT has been mainly attributed to its short half-life in the blood stream, the number of doses per week is the key factor to effective OCT therapy toward suppression of PTH secretion and hypercalcaemia. Thus, we investigated a comparison between daily and thrice-weekly i.v. administration of OCT regarding suppression of PTH secretion and calcaemic action in 5/6 nephrectomized rats as a model for chronic renal failure.

Methods. Model rats of chronic renal failure were made by 5/6 nephrectomy. At 3 months after surgery, they were administered either vehicle or OCT intravenously, daily (0.125 or 0.625 μg/kg) or thrice-weekly (0.6 or 3.0 μg/kg) for 2 weeks.

Results. The data show that 0.625 μg/kg/day (=4.375 μg/kg/week) suppresses PTH secretion with significant increase in calcium levels at 24 h after the final administration, on the other hand, 3.0 μg/kg/ thrice-weekly (=9.0 μg/kg/week) suppresses PTH secretion, although moderate compared with 0.625 μg/kg/day, with a slight (not significant) increase in calcium.

Conclusions. The current clinical mode of OCT therapy, i.v. thrice-weekly administration, is a practically recommendable protocol.

Keywords: calcaemic action; OCT; parathyroid hormone; secondary hyperparathyroidism; uraemia; vitamin D analogue

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.